After DBV Technologies (DBVT) reported topline results for the open label extension of the Phase PEPITES trial, Cantor Fitzgerald analyst Charles Duncan says Aimmune Therapeutics (AIMT) still has the only drug to successfully complete Phase 3 studies and the most efficacious therapeutic for peanut allergy in development. Further, the analyst is "dubious" of DBV's use of "eliciting dose" versus "tolerated dose" as the efficacy measure because he believes that the former may "over-sell" the level of desensitization measured by the dose at which patients respond because investigators can coach beyond symptoms and the more conservative measure would be the dose prior. In a research note titled "Apples Vs Oranges: PALFORZIA Clinical Benefit is Clear, Other Candidate's Not So Much," Duncan keeps an Overweight rating on Aimmune with a $55 price target.